Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Healthcare Company (ACHC) Cash & Equivalents (2016 - 2025)

Acadia Healthcare Company (ACHC) has disclosed Cash & Equivalents for 16 consecutive years, with $133.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 74.62% to $133.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.2 million, a 74.62% increase, with the full-year FY2025 number at $133.2 million, up 74.62% from a year prior.
  • Cash & Equivalents was $133.2 million for Q4 2025 at Acadia Healthcare Company, up from $118.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $196.3 million in Q3 2021 to a low of $63.8 million in Q1 2023.
  • A 5-year average of $115.9 million and a median of $106.1 million in 2023 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 120.87% in 2021; the steepest drop was 64.66% in 2021.
  • Acadia Healthcare Company's Cash & Equivalents stood at $133.8 million in 2021, then dropped by 27.03% to $97.6 million in 2022, then rose by 2.48% to $100.1 million in 2023, then fell by 23.75% to $76.3 million in 2024, then skyrocketed by 74.62% to $133.2 million in 2025.
  • Per Business Quant, the three most recent readings for ACHC's Cash & Equivalents are $133.2 million (Q4 2025), $118.7 million (Q3 2025), and $91.2 million (Q1 2025).